89P Evaluation of exclusion criteria based on renal function in early-phase oncology clinical trials: The EXKID study

Chronic kidney disease (CKD), defined by the KDIGO Consensus as a glomerular filtration rate (GFR) <60 mL/min/1.73 m2 or markers of kidney damage persisting for more than three months, is prevalent in cancer patients due to factors like tumor location, drug-induced toxicities or comorbidities. Despite its high prevalence, CKD remains a frequent exclusion criterion in clinical trials due to concerns over drug pharmacokinetics and potential safety risks, limiting data on cancer treatment efficacy and safety in this population.